Protocol for Women at Increased Risk of Developing Breast Cancer

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

To assess the effects of twelve months of celecoxib administration by evaluating breast tissue needle aspirations, to determine if cell growth can be slowed.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Carol Fabian, MD
• Collaborator: Susan G. Komen Breast Cancer Foundation
• Treatments: Celecoxib

Criteria

Inclusion Criteria:

• women who have a high risk of breast cancer

• older than 18 years

Exclusion Criteria:

• anticoagulants

• marked breast tenderness

• pregnant or within twelve months of breast feeding/childbirth